Parliamentary Search

Written question asked by Stephen Morgan (Labour) on Wednesday, 19 June 2019, in the House of Commons. It was due for an answer on Monday, 24 June 2019 (named day). It was answered by Seema Kennedy (Conservative) on Monday, 24 June 2019 on behalf of the Department of Health and Social Care.

ME/CFS: Medical Treatments

Question

To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of the existing NICE guideline on myalgic encephalomyelitis.

Answer

No specific assessment has been made. The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing evidence-based guidance for the National Health Service to support clinicians and commissioners to plan and deliver services. Clinical guidelines are developed by expert groups that include stakeholder and patient representation. Prior to final publication, they are subject to public consultation and, once published, are routinely reviewed to ensure the guidance reflects the latest available evidence.

In 2007, NICE published the clinical guideline, ‘Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy): Diagnosis and management of CFS/ME in adults and children’. This set out best practice in the diagnosis, treatment, care support of people with the condition.

On 20 September 2017, NICE announced its decision to undertake a full update of the guideline following a review of the latest available evidence on the diagnosis and management of chronic fatigue syndrome/myalgic encephalomyelitis and a public consultation. New guidance is expected in October 2020. More information on this update can be found at the following link:

www.nice.org.uk/guidance/indevelopment/gid-ng10091

Secondary information

Type
Written question
Reference
266885
Session
2017-19
Subjects
ME/CFS Medical treatments
Link
View this Written question on www.parliament.uk